相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Antisense oligonucleotide eluforsen is safe and improves respiratory symptoms in F508DEL cystic fibrosis
Pavel Drevinek et al.
JOURNAL OF CYSTIC FIBROSIS (2020)
Lipoprotein(a) Reduction in Persons with Cardiovascular Disease
Sotirios Tsimikas et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Circular RNA circNRIP1 acts as a microRNA-149-5p sponge to promote gastric cancer progression via the AKT1/mTOR pathway
Xing Zhang et al.
MOLECULAR CANCER (2019)
Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index
Wen Shen et al.
NATURE BIOTECHNOLOGY (2019)
The Clinical Potential of Oligonucleotide Therapeutics against Pancreatic Cancer
Kazuki Takakura et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy
Jonathan E. Rosenberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Noncoding RNAs in cancer therapy resistance and targeted drug development
Wen-Tao Wang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Enhanced Potency of GalNAc-Conjugated Antisense Oligonucleotides in Hepatocellular Cancer Models
Youngsoo Kim et al.
MOLECULAR THERAPY (2019)
Fatty acid conjugation enhances potency of antisense oligonucleotides in muscle
Thazha P. Prakash et al.
NUCLEIC ACIDS RESEARCH (2019)
mRNA levels can be reduced by antisense oligonucleotides via no-go decay pathway
Xue-hai Liang et al.
NUCLEIC ACIDS RESEARCH (2019)
A gapmer antisense oligonucleotide targeting SRRM4 is a novel therapeutic medicine for lung cancer
Masahito Shimojo et al.
SCIENTIFIC REPORTS (2019)
Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease
J. Kim et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Bioconjugated Oligonucleotides: Recent Developments and Therapeutic Applications
Sebastien Benizri et al.
BIOCONJUGATE CHEMISTRY (2019)
Antisense oligonucleotide eluforsen improves CFTR function in F508del cystic fibrosis
Isabelle Sermet-Gaudelus et al.
JOURNAL OF CYSTIC FIBROSIS (2019)
Integrated Assessment of the Clinical Performance of GalNAc3-Conjugated 2′-O-Methoxyethyl Chimeric Antisense Oligonucleotides: I. Human Volunteer Experience
Stanley T. Crooke et al.
NUCLEIC ACID THERAPEUTICS (2019)
Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy
Ferdinandos Skoulidis et al.
NATURE REVIEWS CANCER (2019)
Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data
Charles M. Rudin et al.
NATURE REVIEWS CANCER (2019)
Antisense oligonucleotides: the next frontier for treatment of neurological disorders
Carlo Rinaldi et al.
NATURE REVIEWS NEUROLOGY (2018)
Locked nucleic acid: modality, diversity, and drug discovery
Peter H. Hagedorn et al.
DRUG DISCOVERY TODAY (2018)
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
M. D. Benson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy
E. Mercuri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia
A. A. Thompson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Peptide-conjugated phosphodiamidate oligomer-mediated exon skipping has benefits for cardiac function in mdx and Cmah-/-mdx mouse models of Duchenne muscular dystrophy
Alison M. Blain et al.
PLOS ONE (2018)
Anillin is required for tumor growth and regulated by miR-15a/miR-16-1 in HBV-related hepatocellular carcinoma
Yi-Fan Lian et al.
AGING-US (2018)
NTRK fusion-positive cancers and TRK inhibitor therapy
Emiliano Cocco et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Drugging the RNA World
Matthew D. Disney et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2018)
STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial.
Matthew J. Reilley et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Antisense suppression of the nonsense mediated decay factor Upf3b as a potential treatment for diseases caused by nonsense mutations
Lulu Huang et al.
GENOME BIOLOGY (2018)
Inhibition of STAT3 with the Generation 2.5 Antisense Oligonucleotide, AZD9150, Decreases Neuroblastoma Tumorigenicity and Increases Chemosensitivity
Seiichi Odate et al.
CLINICAL CANCER RESEARCH (2017)
Primary tumor site and anti-EGFR monoclonal antibody benefit in metastatic colorectal cancer: a meta-analysis
Dandan Li et al.
FUTURE ONCOLOGY (2017)
Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial
Kim N. Chi et al.
LANCET ONCOLOGY (2017)
Definition and identification of small RNA sponges: Focus on miRNA sequestration
Melodie Migault et al.
METHODS (2017)
The chemical evolution of oligonucleotide therapies of clinical utility
Anastasia Khvorova et al.
NATURE BIOTECHNOLOGY (2017)
A non-coding function of TYRP1 mRNA promotes melanoma growth
David Gilot et al.
NATURE CELL BIOLOGY (2017)
MicroRNA therapeutics: towards a new era for the management of cancer and other diseases
Rajesha Rupaimoole et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
A Highly Durable RNAi Therapeutic Inhibitor of PCSK9
Kevin Fitzgerald et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol
Kausik K. Ray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
R. S. Finkel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Asialoglycoprotein receptor 1 mediates productive uptake of N-acetylgalactosamine-conjugated and unconjugated phosphorothioate antisense oligonucleotides into liver hepatocytes
Michael Tanowitz et al.
NUCLEIC ACIDS RESEARCH (2017)
Antisense oligonucleotides targeting translation inhibitory elements in 5′ UTRs can selectively increase protein levels
Xue-hai Liang et al.
NUCLEIC ACIDS RESEARCH (2017)
Targeted therapy in severe asthma today: focus on immunoglobulin E
Girolamo Pelaia et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2017)
Preclinical and Clinical Advances of GalNAc-Decorated Nucleic Acid Therapeutics
Yuanyu Huang
MOLECULAR THERAPY-NUCLEIC ACIDS (2017)
Therapeutic miRNA and siRNA: Moving from Bench to Clinic as Next Generation Medicine
Chiranjib Chakraborty et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2017)
Lentiviral vectors can be used for full-length dystrophin gene therapy
John R. Counsell et al.
SCIENTIFIC REPORTS (2017)
The role of peroxiredoxins in cancer
Arianna Nicolussi et al.
MOLECULAR AND CLINICAL ONCOLOGY (2017)
Miravirsen dosing in chronic hepatitis C patients results in decreased microRNA-122 levels without affecting other microRNAs in plasma
M. H. van der Ree et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2016)
Differentiation of mammary tumors and reduction in metastasis upon Malat1 lncRNA loss
Gayatri Arun et al.
GENES & DEVELOPMENT (2016)
Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy
Jerry R. Mendell et al.
ANNALS OF NEUROLOGY (2016)
Antisense molecules: A new class of drugs
Daniel P. Potaczek et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2016)
Melanoma addiction to the long non-coding RNA SAMMSON
Eleonora Leucci et al.
NATURE (2016)
Translation efficiency of mRNAs is increased by antisense oligonucleotides targeting upstream open reading frames
Xue-hai Liang et al.
NATURE BIOTECHNOLOGY (2016)
A microRNA switch regulates the rise in hypothalamic GnRH production before puberty
Andrea Messina et al.
NATURE NEUROSCIENCE (2016)
Efficient Suppression of Hepatitis C Virus Replication by Combination Treatment with miR-122 Antagonism and Direct-acting Antivirals in Cell Culture Systems
Fanwei Liu et al.
SCIENTIFIC REPORTS (2016)
Mipomersen, an Antisense Oligonucleotide to Apolipoprotein B-100, Reduces Lipoprotein(a) in Various Populations With Hypercholesterolemia Results of 4 Phase III Trials
Raul D. Santos et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2015)
Functional correction in mouse models of muscular dystrophy using exon-skipping tricyclo-DNA oligomers
Aurelie Goyenvalle et al.
NATURE MEDICINE (2015)
The emerging role of IncRNAs in cancer
Maite Huarte
NATURE MEDICINE (2015)
AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer
David Hong et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Duchenne muscular dystrophy: current cell therapies
Dorota Sienkiewicz et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2015)
Towards a therapy for Angelman syndrome by targeting a long non-coding RNA
Linyan Meng et al.
NATURE (2015)
A day in the life of the spliceosome
A. Gregory Matera et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2014)
Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice
Thazha P. Prakash et al.
NUCLEIC ACIDS RESEARCH (2014)
DNA-based digital tension probes reveal integrin forces during early cell adhesion
Yun Zhang et al.
NATURE COMMUNICATIONS (2014)
The Noncoding RNA MALAT1 Is a Critical Regulator of the Metastasis Phenotype of Lung Cancer Cells
Tony Gutschner et al.
CANCER RESEARCH (2013)
Mipomersen Sodium: First Global Approval
Philip Hair et al.
DRUGS (2013)
Gene therapy on the move
Kerstin B. Kaufmann et al.
EMBO MOLECULAR MEDICINE (2013)
MicroRNAs and other non-coding RNAs as targets for anticancer drug development
Hui Ling et al.
NATURE REVIEWS DRUG DISCOVERY (2013)
Exon skipping and PRO044 in Duchenne muscular dystrophy: Extending the program
A. Ferlini et al.
NEUROMUSCULAR DISORDERS (2013)
Treatment of HCV Infection by Targeting MicroRNA
Harry L. A. Janssen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Single-molecule study of the CUG repeat-MBNL1 interaction and its inhibition by small molecules
Amin Haghighat Jahromi et al.
NUCLEIC ACIDS RESEARCH (2013)
Mipomersen: A Safe and Effective Antisense Therapy Adjunct to Statins in Patients With Hypercholesterolemia
Daniel N. Ricotta et al.
CARDIOLOGY IN REVIEW (2012)
Targeting nuclear RNA for in vivo correction of myotonic dystrophy
Thurman M. Wheeler et al.
NATURE (2012)
Targeted therapies: how personal should we go?
Miriam Martini et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
Sustained Therapeutic Reversal of Huntington's Disease by Transient Repression of Huntingtin Synthesis
Holly B. Kordasiewicz et al.
NEURON (2012)
Mechanisms of activation of the paternally expressed genes by the Prader-Willi imprinting center in the Prader-Willi/Angelman syndromes domains
Shiri Rabinovitz et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Pip6-PMO, A New Generation of Peptide-oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity for DMD Treatment
Corinne Betts et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2012)
Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia
Fatima Akdim et al.
EUROPEAN HEART JOURNAL (2011)
Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model
Yimin Hua et al.
NATURE (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Angelman syndrome: insights into genomic imprinting and neurodevelopmental phenotypes
Angela M. Mabb et al.
TRENDS IN NEUROSCIENCES (2011)
Long-term improvement in mdx cardiomyopathy after therapy with peptide-conjugated morpholino oligomers
Natee Jearawiriyapaisarn et al.
CARDIOVASCULAR RESEARCH (2010)
Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model
Yimin Hua et al.
GENES & DEVELOPMENT (2010)
Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial
Frederick J. Raal et al.
LANCET (2010)
Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management
Katharine Bushby et al.
LANCET NEUROLOGY (2010)
Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia
Marina Cavazzana-Calvo et al.
NATURE (2010)
Progression of transthyretin amyloid neuropathy after liver transplantation
Juris J. Liepnieks et al.
NEUROLOGY (2010)
A Locked Nucleic Acid Antisense Oligonucleotide (LNA) Silences PCSK9 and Enhances LDLR Expression In Vitro and In Vivo
Nidhi Gupta et al.
PLOS ONE (2010)
Therapeutic Silencing of MicroRNA-122 in Primates with Chronic Hepatitis C Virus Infection
Robert E. Lanford et al.
SCIENCE (2010)
No-go decay: a quality control mechanism for RNA in translation
Yuriko Harigaya et al.
WILEY INTERDISCIPLINARY REVIEWS-RNA (2010)
MicroRNAs: Target Recognition and Regulatory Functions
David P. Bartel
CELL (2009)
Mutational Spectrum of DMD Mutations in Dystrophinopathy Patients: Application of Modern Diagnostic Techniques to a Large Cohort
Kevin M. Flanigan et al.
HUMAN MUTATION (2009)
The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine
Jeffrey S. Ross et al.
ONCOLOGIST (2009)
Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophy
Susan A. M. Mulders et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Locked nucleic acid as a novel class of therapeutic agents
Rakesh N. Veedu et al.
RNA BIOLOGY (2009)
Expanded CTG repeats within the DMPK 3′ UTR causes severe skeletal muscle wasting in an inducible mouse model for myotonic dystrophy
James P. Orengo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Local dystrophin restoration with antisense oligonucleotide PRO051
Judith C. van Deutekom et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Sequence variations in PCSK9, low LDL, and protection against coronary heart disease
JC Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Formation and repair of interstrand cross-links in DNA
DM Noll et al.
CHEMICAL REVIEWS (2006)
Silencing of microRNAs in vivo with 'antagomirs'
J Krützfeldt et al.
NATURE (2005)
Pharmacokinetics and biodistribution of phosphorodiamidate morpholino antisense oligomers
A Amantana et al.
CURRENT OPINION IN PHARMACOLOGY (2005)
A genetic screen for candidate tumor suppressors identifies REST
TF Westbrook et al.
CELL (2005)
MicroRNAs: Genomics, biogenesis, mechanism, and function
DP Bartel
CELL (2004)
Revealing the world of RNA interference
CC Mello et al.
NATURE (2004)
Crystal structure of argonaute and its implications for RISC slicer activity
JJ Song et al.
SCIENCE (2004)
Antisense-induced multiexon skipping for Duchenne muscular dystrophy makes more sense
A Aartsma-Rus et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2004)
Tabulation of human transthyretin (TTR) variants, 2003
LH Connors et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2003)
Hammerhead ribozyme-mediated destruction of nuclear foci in myotonic dystrophy myoblasts
MA Langlois et al.
MOLECULAR THERAPY (2003)
Antisense technologies - Improvement through novel chemical modifications
J Kurreck
EUROPEAN JOURNAL OF BIOCHEMISTRY (2003)
Tamoxifen: A most unlikely pioneering medicine
VC Jordan
NATURE REVIEWS DRUG DISCOVERY (2003)
Angelman syndrome: a review of the clinical and genetic aspects
J Clayton-Smith et al.
JOURNAL OF MEDICAL GENETICS (2003)
Dystrophin and mutations: one gene, several proteins, multiple phenotypes
F Muntoni et al.
LANCET NEUROLOGY (2003)
Antisense properties of tricyclo-DNA
D Renneberg et al.
NUCLEIC ACIDS RESEARCH (2002)
Fomivirsen - Clinical pharmacology and potential drug interactions
RS Geary et al.
CLINICAL PHARMACOKINETICS (2002)
The mononucleotide-dependent, nonantisense mechanism of action of phosphodiester and phosphorothioate oligonucleotides depends upon the activity of an ecto-5′-nucleotidase
M Koziolkiewicz et al.
BLOOD (2001)
Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells
JCT van Deutekom et al.
HUMAN MOLECULAR GENETICS (2001)
分享论文
